Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.1 USD | -0.86% | -3.72% | +338.96% |
May. 08 | Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating | MT |
May. 08 | Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+338.96% | 2.44B | C | ||
+33.63% | 50.93B | B- | ||
-0.09% | 42.12B | B | ||
+49.62% | 42.05B | A | ||
-4.96% | 29.18B | C | ||
+11.18% | 26.02B | B- | ||
-21.95% | 18.9B | B | ||
+8.61% | 13.21B | B+ | ||
+24.73% | 12.17B | B+ | ||
+28.31% | 12.16B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JANX Stock
- Ratings Janux Therapeutics, Inc.